ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Metabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large-Scale, Multicenter Study.
Yongjie Xu, Jiachen Wang, Chunmeng Ding, Changfa Xia, Yunyong Liu, Yuanjie Zheng, Sheng Chang, Shaokai Zhang, Yutong He, Ruifang Sun and 4 more
Abstract read
In one paragraphArticle in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Yongjie Xu *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0001-8417-3168 Jiachen Wang *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0002-6846-7550 Chunmeng Ding *School of Biomedical Engineering, Institute of Medical Robotics and Shanghai Academy of Experimental Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0009-0006-3930-9146 Changfa Xia *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0001-9097-1369 Yunyong Liu *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Guangdong, China.
Yuanjie ZhengNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0009-0001-9576-1106 Sheng ChangNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Guangdong, China.
Shaokai ZhangDepartment of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.
Ruifang SunDepartment of Tumor Biobank, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Shanxi, China.ORCID https://orcid.org/0000-0002-4791-3734 Yunfeng XiThe Inner Mongolia Autonomous Region Center for Disease Control and Prevention, Inner Mongolia, China.
Wanqing ChenNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0002-1159-1884 Funding
CAMS Innovation Fund for Medical Sciences (CIFMS) 2025-I2M-XHXX-053National High Level Hospital Clinical Research Funding and Cooperation Fund of CHCAMS and SZCH CFA202201003National Natural Science Foundation of China 82574179The Beijing High-LevelInnovation and Entrepreneurship Talent Support Program,Leading Talent Projects G202513008
6 · The paper itselfAbstract
The poor prognosis of liver cancer (LC) highlights the urgent need for more effective strategies for early detection. We conducted a large, multicenter study to develop and validate a serum metabolic signature for LC diagnosis. Using high-throughput nanoparticle-enhanced laser desorption/ionization mass spectrometry, we profiled serum metabolites from 1,924 participants in discovery cohort recruited across 11 clinical centers and 225 participants in independent external validation cohort from two additional centers. A nine-metabolite signature combined with alpha-fetoprotein achieved excellent discriminatory performance, with an AUC of 0.92 in the discovery cohort and 0.93 in the external validation cohort. The combined model also showed good sensitivity for early-stage LC, reaching 0.85 and 0.78 in the two cohorts, respectively, and performed particularly well for hepatocellular carcinoma, with AUCs of 0.94 and 0.93. Exploratory analyses suggested potential utility for intrahepatic cholangiocarcinoma diagnosis. Mendelian randomization analysis supported a potential causal association between nicotinamide (NAM) levels and LC risk. Functional studies showed that NAM promotes LC cell proliferation, migration, and invasion, through an NAD
Indexed as
early diagnosisHIF1αliver cancermetabolitesnicotinamide
Identifiers
PMID42829912
PMCPMC13634481
What Socratic holds
Textmetadata
Read underepoch 390